Jim Reddoch, PhD, is Executive Vice President for Research and Investments at Royalty Pharma. He leads a team of professionals who focus on sourcing and analyzing new opportunities and partnerships. In his 10-year tenure at Royalty Pharma, the firm has invested close to $12 billion in over 20 transactions in both approved and unapproved assets. In the past five years, Royalty Pharma has pioneered the creation of synthetic royalties to fund individual clinical-stage products.
Prior to joining Royalty Pharma in 2008, Jim was Senior Vice President and Head of Healthcare Research and FBR Capital Markets, where he published on biopharmaceutical stocks and led a team of equity research analysts in five healthcare verticals. His prior experience includes serving as a biotechnology analyst at Bank of America and CIBC World Markets. Jim has a PhD in Biochemistry and Molecular Genetics from University of Alabama at Birmingham, and later worked as a postdoctoral fellow at Yale University in the lab of Peter Glazer. He moonlighted at Yale’s Office of Cooperative Research. He has a BA from Furman University.
He is on the board of Avillion, a London-based drug development company also funded by Clarus and Abingworth. Jim serves on Memorial Sloan Kettering Cancer Center’s external review committee for its Technology Development Fund (TDF)